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Objectives. This study was designed to compare the preventive
effect of nitrate tolerance between carvedilol with antioxidant
properties and arotinolol without antioxidant properties.
Background. The attenuation of cyclic guanosine monophos-
phate (cGMP) production due to inactivation of guanylate cyclase
by increased superoxide has been reported as a mechanism of
nitrate tolerance. Carvedilol has been known to combine alpha-
and beta-blockade with antioxidant properties.
Methods. To evaluate the preventive effect of nitrate tolerance,
24 patients with untreated hypertension were randomized to
receive either carvedilol (10 mg twice a day [carvedilol group, n 5
8]), arotinolol (10 mg twice a day [arotinolol group, n 5 8]), or
placebo (placebo group, n 5 8). Vasodilatory response to nitro-
glycerin (NTG) was assessed with forearm plethysmography by
measuring the change in forearm blood flow (FBF) before and
5 min after sublingual administration of 0.3 mg NTG, and at the
same time blood samples were taken from veins on the opposite
side to measure platelet cGMP. Plethysmography and blood
sampling were obtained serially at baseline (day 0), 3 days after
carvedilol, arotinolol or placebo administration (day 3) and 3 days
after application of a 20 mg/24 h NTG tape concomitantly with
carvedilol, arotinolol or placebo (day 6).
Results. There was no significant difference in the response of
FBF (%FBF) and cGMP (%cGMP) to sublingual administration
of NTG on days 0 and 3 among the three groups. On day 6, %FBF
and %cGMP were significantly lower in the arotinolol group and
the placebo group than days 0 and 3, but these parameters in the
carvedilol group were maintained.
Conclusions. The results indicated that carvedilol with antiox-
idant properties may prevent the development of nitrate tolerance
during continuous therapy with NTG compared with arotinolol
without antioxidant properties.
(J Am Coll Cardiol 1998;32:1201–6)
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Organic nitrates are widely used in cardiovascular medicine,
but their continuous administration can result in the rapid
development of tolerance (1–3). The underlying mechanisms
responsible for nitrate tolerance probably are multifactorial (4)
and may include neurohormonal counterregulatory mecha-
nisms (5), intravascular volume expansion (6) or intrinsic
abnormalities such as desensitization of the target enzyme
guanylate cyclase (7) or a decrease in nitroglycerin (NTG)
biotransformation (8). Recent experimental data have demon-
strated that nitrate tolerance is associated with increased
vascular superoxide anion production (9). Therefore, antioxi-
dant may be effective in the prevention of the development of
nitrate tolerance. Carvedilol has recently been reported as
having a beneficial effect on the survival of patients with heart
failure (10–12), and carvedilol has been known to combine
alpha- and beta-blockade with antioxidant properties (13–16).
On the other hand, arotinolol is an alpha- and beta-blocker
without antioxidant properties which is available in Japan and
the ratio of alpha to beta is similar to carvedilol (alpha:beta 5
1:8) (17,18). Therefore, to investigate the effect of carvedilol
on nitrate tolerance, we compared the vasodilatory response
and the change of platelet cyclic guanosine monophosphate
(cGMP) level during continuous administration of NTG be-
tween carvedilol with antioxidant properties and arotinolol
without antioxidant properties in a randomized, double-blind,
placebo-controlled study.
Methods
Patient population. The study population was composed of
24 patients with untreated hypertension (18 men and 6
women) ranging in age from 44 to 69 years, who had no history
of renal or cardiac disease and who had normal findings on
physical examination, serum electrolyte, cholesterol, blood
urea nitrogen, creatinine levels and urine analysis. No subjects
were taking medications at the time of the study. Patients’
characteristics are shown in Table 1.
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Study protocol (Figure 1). We measured the vasodilator
response to sublingual administration of NTG by plethysmog-
raphy and platelet cGMP at baseline (day 0), after 3 days of
administration of carvedilol, arotinolol or placebo (day 3) and
after 3 days following the application of a 20 mg/24 h NTG
tape concomitantly with carvedilol, arotinolol or placebo (day
6). An 18-gauge heparin lock was inserted in the contralateral
forearm to allow venous blood sampling for measurements of
the platelet cGMP level.
The baseline forearm blood flow (FBF) was recorded by
plethysmography before and 5 min after administration of
0.3 mg of sublingual NTG on day 0. Subjects were then
randomized by a double-blind parallel design to receive either
carvedilol 10 mg twice a day (carvedilol group, n 5 8),
arotinolol 10 mg twice a day (arotinolol group, n 5 8) or
placebo twice a day (placebo group, n 5 8). Subjects returned
3 days after treatment with carvedilol, arotinolol or placebo for
measurements of FBF and platelet cGMP before and after
administration of sublingual NTG. A 10-mg NTG tape (Mil-
lisrol Tape, Nippon Kayaku, Tokyo, Japan) was then applied
twice a day. Final measurements were obtained 3 days after
treatment with combined continuous transdermal NTG and
carvedilol, arotinolol or placebo.
The study protocol was approved by the ethics committees
of KINU Medical Association Hospital, Mitsukaido, Japan,
and University of Tsukuba, Tsukuba, Japan, and written
informed consent for participation in this study was obtained
from all subjects.
Assessment of the vasodilator response to NTG. To eval-
uate the vasodilator response to NTG, the FBF was measured
with a mercury-in-silastic strain gauge plethysmograph and the
venous occlusion technique. The strain gauge was placed 5 cm
below the antecubital crease and connected to a calibrated
plethysmography. The FBF is expressed as the rate of change
in the forearm volume (ml/min/100 ml forearm). The pressure
in the venous occlusion or congesting cuff was 40 mm Hg.
Circulation to the hand was arrested during determinations of
FBF by inflation of a cuff around the wrist to suprasystolic
pressure. We used the average of three measurements made at
15-s intervals to represent the FBF.
Preparation of platelet cGMP. Blood samples were drawn
into syringes containing 5 mM EDTA and a cGMP phospho-
diesterase inhibitor (1023 M 2-O-propoxyphenyl-8-azapurin-6-
one dissolved in 1% triethanolamine). Platelet-rich plasma and
platelet-poor plasma were prepared immediately after blood
sampling by centrifugation at 200 g for 20 min. Platelet-rich
plasma was further centrifuged at 2,500 g for 10 min, and the
supernatant was discarded. The pellet was suspended in mod-
ified Tyrode’s solution (containing 0.35% bovine serum albu-
min and 5 mM HEPES, pH 7.35) to obtain a final platelet
count of 2 to 3 3 106 platelets/ml. The samples were stored
frozen at 270°C until analysis (19).
Platelet cGMP assay. Trichloroacetic acid (0.5 ml in a final
concentration of 6%) was added to 1 ml of the platelet
preparation. After centrifugation at 2,500 g for 20 min, trichlo-
roacetic acid was extracted four times from the supernatant
with water-saturated ether. The aqueous phase was then
assayed for cGMP using a commercially available radioimmu-
noassay kit (Yamasa Shoyu, Choshi, Japan) (20). The results
are expressed in picomoles per 109 platelets. The coefficients of
variation averaged 3.4% for intraassay error and 11.9% for
interassay error.
Statistical analysis. Results are expressed as the mean 6
SD for FBF and platelet cGMP level. Differences among the
test days or differences before and after sublingual administra-
tion of NTG were analyzed by repeated measures of a one-way
analysis of variance with Bonferroni’s test, and differences
among groups were analyzed by Student t test. A level p , 0.05
was accepted as statistically significant.
Results
Heart rate and blood pressure. Heart rates were not
different among the three groups on day 0. Heart rates in the
carvedilol group and the arotinolol group were significantly
decreased on days 3 and 6, but heart rates in the placebo group
did not change during study (Table 2).
Systolic blood pressure was not different among the three
Figure 1. Study protocol. NTG 5 nitroglycerin.
Table 1. Patient Characteristics
Carvedilol
Group (n 5 8)
Arotinolol
Group (n 5 8)
Placebo Group
(n 5 8)
Age (yrs) 57 6 8 56 6 9 57 6 7
Male/female 6/2 7/1 5/3
Heart rate (beats/min) 68 6 5 67 6 5 68 6 6
Systolic pressure (mm Hg) 178 6 15 175 6 14 174 6 16
Diastolic pressure (mm Hg) 98 6 11 101 6 14 100 6 13
Total cholesterol (mg/dl) 184 6 24 182 6 21 185 6 25
Triglyceride (mg/dl) 124 6 35 128 6 26 126 6 28
Creatinine (mg/dl) 0.8 6 0.2 0.8 6 0.3 0.8 6 0.3
Abbreviations and Acronyms
cGMP 5 cyclic guanosine monophosphate
FBF 5 forearm blood flow
NTG 5 nitroglycerin
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groups on day 0 before and after sublingual administration of
NTG. On day 3 systolic blood pressure before sublingual
administration NTG was significantly decreased in the carve-
dilol group and the arotinolol group and significantly lower
than the placebo group. Sublingual administration of NTG
significantly decreased systolic blood pressure in the three
groups. On day 6, systolic blood pressure in the carvedilol
group before sublingual administration of NTG was signifi-
cantly decreased compared with day 3. But systolic blood
pressure in the arotinolol group and the placebo group before
sublingual administration of NTG was not changed compared
with day 3. After sublingual administration of NTG, systolic
blood pressure was significantly decreased in the three groups.
However, on day 6, systolic blood pressure after sublingual
administration of NTG was lower in the carvedilol group than
in the arotinolol group and the placebo group (Table 2).
Forearm blood flow. On day 0, there was no significant
difference in the FBF before sublingual administration of NTG
among the three groups. Sublingual administration of NTG
increased the FBF in the three groups on day 0. On day 3,
sublingual administration of NTG increased the FBF in the
three groups, but the FBF before and after sublingual admin-
istration of NTG was higher in the carvedilol group and the
arotinolol group than in the placebo group. There was no
difference in FBF between the carvedilol group and the
arotinolol group. On day 6, sublingual administration of NTG
increased the FBF in the three groups, but the FBF after
sublingual administration of NTG was significantly smaller in
the arotinolol group and the placebo group than on day 3. In
the carvedilol groups, the FBF was higher before and after
sublingual administration of NTG than on day 3, and the FBF
after sublingual administration of NTG was significantly
greater in the carvedilol group than in the arotinolol group and
the placebo group (Table 3).
There was no significant difference in the percent increase
in the FBF on days 0 and 3 among the three groups (day 0:
carvedilol group, 31 6 12%; arotinolol group, 30 6 11%;
placebo group, 31 6 9%; day 3: carvedilol group, 32 6 9%;
arotinolol group, 33 6 12%; placebo group, 31 6 13%). The
percent increases in the arotinolol group and the placebo
group were significantly lower on day 6 (arotinolol group, 18 6
7%; placebo group, 15 6 8%) than on days 0 and 3. In the
carvedilol group, the percent increase in the FBF after sublin-
gual administration of NTG was maintained on day 6 (27 6
12%) and was significantly greater than that of the arotinolol
group and the placebo group. (Fig. 2).
Platelet cGMP level. The platelet cGMP level was signifi-
cantly increased after sublingual administration of NTG in the
three groups on days 0 and 3. There was no significant
difference among the three groups on days 0 and 3.
On day 6, the platelet cGMP levels in the arotinolol group
and the placebo group were significantly lower than those on
days 0 and 3, both before and after sublingual administration
of NTG, whereas the platelet cGMP level in the carvedilol
group on day 6 was significantly increased after sublingual
administration of NTG, and was significantly higher than in the
arotinolol group and the placebo group (Table 3).
Table 2. Heart Rate (beats/min) and Systolic Blood Pressure
(mm Hg)
Carvedilol
Group
Arotinolol
Group
Placebo
Group
Heart rate
Day 0
Before 68 6 5 67 6 5 68 6 6
After 67 6 8 69 6 8 67 6 9
Day 3
Before 59 6 9† 60 6 7† 68 6 7
After 58 6 8† 61 6 9† 69 6 8
Day 6
Before 58 6 6† 58 6 8† 70 6 9
After 59 6 7† 57 6 9† 71 6 6
Systolic blood pressure
Day 0
Before 178 6 15 175 6 14 174 6 16
After 154 6 16* 156 6 15* 155 6 18*
Day 3
Before 153 6 15† 156 6 13† 170 6 18
After 140 6 12*† 145 6 15*† 157 6 15*
Day 6
Before 148 6 18†‡ 157 6 15† 171 6 15
After 134 6 16*†‡ 148 6 14*† 164 6 18*
Data are expressed as mean 6 SD. Before 5 before sublingual administra-
tion of nitroglycerin; after 5 after sublingual administration of nitroglycerin.
*p , 0.05 vs. before; †p , 0.05 vs. day 0; ‡p , 0.05 vs. day 3.
Table 3. Forearm Blood Flow (FBF, ml/min/100 ml arm) and
Platelet cGMP Levels (pmol/109 PLT)
Carvedilol
Gruop
Arotinolol
Group
Placebo
Group
FBF
Day 0
Before 2.2 6 0.7 2.4 6 0.6 2.3 6 0.8
After 2.9 6 0.8* 3.1 6 0.5* 3.0 6 0.7*
Day 3
Before 3.2 6 0.6† 3.5 6 0.6† 2.5 6 0.6
After 4.2 6 0.7*† 4.7 6 0.7*† 3.3 6 0.5*
Day 6
Before 3.8 6 0.6†‡ 3.5 6 0.8† 2.4 6 0.8
After 4.8 6 0.5*†‡ 4.1 6 0.7*†‡ 2.6 6 0.8*‡
cGMP
Day 0
Before 0.41 6 0.17 0.40 6 0.14 0.40 6 0.14
After 0.50 6 0.14* 0.55 6 0.17* 0.56 6 0.11*
Day 3
Before 0.43 6 0.14 0.45 6 0.20 0.42 6 0.14
After 0.60 6 0.20* 0.63 6 0.17* 0.58 6 0.14*
Day 6
Before 0.39 6 0.20 0.32 6 0.14† 0.28 6 0.14†
After 0.51 6 0.17*‡ 0.36 6 0.17*† 0.31 6 0.17*†
Data are expressed as mean 6 SD. Before 5 before sublingual administra-
tion of nitroglycerin; After 5 after sublingual administration of nitroglycerin.
*p , 0.05 vs. before; †p , 0.05 vs. days 0 and 3; ‡p , 0.05 vs. the arotinolol and
placebo groups.
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There was no difference in the percent increase in the
platelet cGMP level among the three groups on days 0 and 3
(day 0: carvedilol group, 39 6 10%; arotinolol group, 38 6
11%; placebo group, 39 6 12%; day 3: carvedilol group, 40 6
13%; arotinolol group, 39 6 14%; placebo group, 38 6 14%).
The percent increase in cGMP level in the arotinolol group
and the placebo group were significantly lower on day 6
(arotinolol group, 12 6 9%; placebo group, 11 6 8%) com-
pared with that on days 0 and 3. The percent increase in the
platelet cGMP level in the carvedilol group was maintained on
day 6 (31 6 11%) and was significantly greater than that of the
arotinolol group and the placebo group (Fig. 3).
Discussion
This placebo-controlled, double-blind study demonstrated
that carvedilol, during transdermal application of NTG, main-
tained the response of vasodilation and the intracellular pro-
duction of cGMP after sublingual administration of NTG, but
arotinolol did not have these effects. These findings suggest
that carvedilol, an alpha- and beta-blocker with antioxidant
properties, may prevent nitrate tolerance during continuous
application of NTG.
Mechanisms of nitrate tolerance. The mechanism of ni-
trate tolerance is multifactorial (4,21,22). Previous investiga-
tors proposed four possible mechanisms of nitrate tolerance
after chronic exposure: 1) desensitization of the target enzyme
guanylate cyclase (7); 2) an increase in phosphodiesterase
activity (23); 3) intracellular sulfhydryl group depletion (24);
and 4) impaired NTG biotransformation (25). However, on the
basis of these mechanisms, attempts to prevent or reverse
tolerance with sulfhydryl group donors (6,26,27) or
angiotensin-converting enzyme inhibitors (28–30) have not
been uniformly successful. Mu¨nzel et al. (9) recently demon-
strated that enhanced angiotensin II activities resulted in
increased production of oxygen-derived radicals that inhibit
the dilator action of NTG-derived nitric oxide. An increase in
oxidative stress due to an increase in free radicals may be one
of the contributing factors in the mechanisms of nitrate
tolerance. Therefore, we thought that an antioxidant may
prevent nitrate tolerance.
Preventive effects of carvedilol on nitrate tolerance. Some
investigations based on those proposed mechanisms have
demonstrated preventive effects of antioxidants on nitrate
tolerance. In an experimental animal study, Bassenge and Fink
(31) demonstrated that vitamin C prevented nitrate tolerance
in the dilatation of the coronary artery and the production of
platelet cGMP. However, Mu¨nzel et al. (9) showed negative
data by using superoxide dismutase in vitro. We cannot explain
why superoxide dismutase did not prevent nitrate tolerance in
the work by Mu¨nzel et al. In clinical studies we demonstrated
that vitamins E and C could prevent nitrate tolerance (32–34).
The effects of hydralazine on nitrate tolerance as a vasodilator
with antioxidant properties have been also reported (35,36).
Carvedilol, in addition to being an adrenergic antagonist
and a vasodilator, appears to be an antioxidant and free radical
scavenger as well (13–16). On the other hand, arotinolol has
been reported as an alpha- and beta-blocker without antioxi-
dant properties (Fig. 4) (17,18). In the present study we
observed nitrate tolerance in FBF and platelet cGMP levels
and showed the attenuation of the change of FBF and platelet
cGMP levels after sublingual administration of NTG in the
placebo group. These phenomena were also observed in the
arotinolol group. Therefore, we concluded that arotinolol
without antioxidant properties might not prevent nitrate toler-
ance, and that carvedilol with antioxidant properties might
prevent the attenuation of the response in the vasodilatory
response and the intracellular production of cGMP after
sublingual administration of NTG during continuous trans-
dermal application of NTG. To our knowledge, the present
study provides the first evidence in the clinical investigation
that the development of nitrate tolerance may be prevented by
the supplementation with carvedilol.
Study limitations. There are some limitations to the
present study. First, we measured the platelet cGMP level to
Figure 3. The percentage of increase in platelet cGMP level after
sublingual administration of NTG. Data are expressed as the mean
value 6 SD. **p , 0.01 vs. days 0 and 3; †p , 0.05 between the two
groups. cGMP 5 cyclic guanosine monophosphate.
Figure 2. The percentage of increase in the FBF after sublingual
administration of NTG. Data are expressed as the mean value 6 SD.
**p , 0.01 vs. days 0 and 3; †p , 0.05 between the two groups.
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evaluate the intracellular production of cGMP. The in vivo
effects of NTG on the intracellular production of cGMP in the
vascular smooth muscle cells can only be evaluated in biopsies.
Nitroglycerin activates soluble guanylate cyclase in platelets,
and the increased level of platelet cGMP inhibits platelet
adhesion (37,38). Platelets predominately contain the soluble
guanylate cyclase (39,40). Therefore, platelets are an appro-
priate material for the clinical measurement of intracellular
cGMP. In a previous study, we demonstrated that the platelet
cGMP level can be used as an indicator of the effects of NTG
and the development of nitrate tolerance (19). Second, we
measured heart rate and blood pressure 5 min after sublingual
administration of NTG at the same time of measurements of
FBF and platelet cGMP levels. Despite about a 20 mm Hg fall
in systolic blood pressure, the heart rate on day 0 did not
change after sublingual administration of NTG in our results.
We did observe an increase in heart rate 3 min after sublingual
administration of NTG in electrocardiogram monitor, but the
heart rate recovered until 5 min after sublingual administration
of NTG. So we speculated that heart rate had been compen-
sated 5 min after sublingual administration of NTG. We also
observed the further decrease in blood pressure on day 6
compared with that on day 3 in the carvedilol group, but there
was no difference in blood pressure between that on days 3 and
6 in the arotinolol group. We speculated further that the fall in
blood pressure in the carvedilol groups was a result of main-
tained NTG effects without nitrate tolerance. However, we
must note the possibility that the further fall in blood pressure
in the carvedilol group on day 6 may represent not only an
NTG effect but also continuous greater effect of carvedilol.
Third, we demonstrated the preventive effects of carvedilol on
nitrate tolerance in FBF and platelet cGMP, but we did not
measure any indicator of peroxynitrate generation by oxygen
free radicals (e.g., nitrotyrosine). Therefore, it is a speculation
whether the mechanism of carvedilol on the prevention of
nitrate tolerance is due to antioxidant properties. Fourth, we
evaluated the effect of a single dose of carvedilol (10 mg twice
a day) or arotinolol (10 mg twice a day) in this study. Because
we can observe similar responses in heart rate and blood
pressure on day 3, we thought that the effect of this dosage of
carvedilol or arotinolol was similar as alpha- and beta-blockade
in this study. We need further studies of adequate dosage of
carvedilol to prevent nitrate tolerance in patients with ischemic
heart disease or chronic heart failure. Finally, the present study
demonstrated the preventive effect of carvedilol on nitrate
tolerance in patients with untreated hypertension. Therefore,
we cannot implicate our results directly to patients with
coronary artery disease or chronic heart failure. We need
further clinical studies in patients with ischemic heart disease
or chronic heart disease.
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